We illustrate this method by application to the analysis of the response of PI3K/PTEN/AKT signaling to a drug combination targeting the HER2 receptor and a protein in the DSP, PI3K, which were established to be promising drug targets in both mono- and combination therapy in different cancers (1, 15, 42). Here, PIK3CA is linked to cancer.